Royal Bank of Canada’s Concert Pharmaceuticals, Inc. CNCE Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q1 | – | Sell |
-87,212
| Closed | -$509K | – | 7776 |
|
|
2022
Q4 | $509K | Buy |
87,212
+86,329
| +9,777% | +$454K | ﹤0.01% | 4095 |
|
|
2022
Q3 | $5K | Buy |
883
+843
| +2,108% | +$5.11K | ﹤0.01% | 6777 |
|
|
2022
Q2 | $0 | Hold |
40
| – | – | ﹤0.01% | 8032 |
|
|
2022
Q1 | $0 | Hold |
40
| – | – | ﹤0.01% | 8200 |
|
|
2021
Q4 | $0 | Buy |
+40
| New | +$133 | ﹤0.01% | 8090 |
|
|
2021
Q3 | – | Sell |
-2,253
| Closed | -$10K | – | 8018 |
|
|
2021
Q2 | $10K | Sell |
2,253
-360
| -14% | -$1.52K | ﹤0.01% | 6888 |
|
|
2021
Q1 | $13K | Buy |
2,613
+1,072
| +70% | +$8.66K | ﹤0.01% | 6700 |
|
|
2020
Q4 | $19K | Buy |
1,541
+1,492
| +3,045% | +$17K | ﹤0.01% | 6097 |
|
|
2020
Q3 | $0 | Sell |
49
-17
| -26% | -$168 | ﹤0.01% | 7081 |
|
|
2020
Q2 | $1K | Sell |
66
-66
| -50% | -$633 | ﹤0.01% | 6527 |
|
|
2020
Q1 | $1K | Sell |
132
-1,262
| -91% | -$12.4K | ﹤0.01% | 6546 |
|
|
2019
Q4 | $13K | Buy |
+1,394
| New | +$9.88K | ﹤0.01% | 6058 |
|
|
2019
Q3 | – | Sell |
-20
| Closed | – | – | 7285 |
|
|
2019
Q2 | $0 | Buy |
+20
| New | +$215 | ﹤0.01% | 7312 |
|
|
2018
Q4 | – | Sell |
-262
| Closed | -$4K | – | 7283 |
|
|
2018
Q3 | $4K | Sell |
262
-7,499
| -97% | -$118K | ﹤0.01% | 6365 |
|
|
2018
Q2 | $131K | Buy |
7,761
+39
| +0.5% | +$757 | ﹤0.01% | 4659 |
|
|
2018
Q1 | $177K | Sell |
7,722
-2,884
| -27% | -$64.1K | ﹤0.01% | 4386 |
|
|
2017
Q4 | $274K | Buy |
10,606
+8,956
| +543% | +$180K | ﹤0.01% | 4227 |
|
|
2017
Q3 | $24K | Buy |
1,650
+1,627
| +7,074% | +$23.6K | ﹤0.01% | 5866 |
|
|
2017
Q2 | $0 | Sell |
23
-361
| -94% | -$5.32K | ﹤0.01% | 6868 |
|
|
2017
Q1 | $6K | Sell |
384
-5,639
| -94% | -$67.6K | ﹤0.01% | 6165 |
|
|
2016
Q4 | $62K | Buy |
6,023
+998
| +20% | +$9.12K | ﹤0.01% | 5136 |
|
|
2016
Q3 | $51K | Buy |
5,025
+25
| +0.5% | +$273 | ﹤0.01% | 5151 |
|
|
2016
Q2 | $56K | Hold |
5,000
| – | – | ﹤0.01% | 5068 |
|
|
2016
Q1 | $68K | Sell |
5,000
-100
| -2% | -$1.44K | ﹤0.01% | 4961 |
|
|
2015
Q4 | $97K | Sell |
5,100
-1,083
| -18% | -$23.5K | ﹤0.01% | 4944 |
|
|
2015
Q3 | $116K | Sell |
6,183
-277
| -4% | -$4.71K | ﹤0.01% | 4696 |
|
|
2015
Q2 | $95K | Buy |
6,460
+5,960
| +1,192% | +$90.8K | ﹤0.01% | 4860 |
|
|
2015
Q1 | $8K | Hold |
500
| – | – | ﹤0.01% | 5638 |
|
|
2014
Q4 | $7K | Sell |
500
-800
| -62% | -$10.3K | ﹤0.01% | 5724 |
|
|
2014
Q3 | $16K | Buy |
1,300
+1,000
| +333% | +$9.7K | ﹤0.01% | 5350 |
|
|
2014
Q2 | $3K | Hold |
300
| – | – | ﹤0.01% | 5676 |
|
|
2014
Q1 | $4K | Buy |
+300
| New | +$4.24K | ﹤0.01% | 5631 |
|
Royal Bank of Canada's CNCE Position: Q1 2023 in Review
Royal Bank of Canada sold out of Concert Pharmaceuticals, Inc. (CNCE) in Q1 2023, closing a stake of 87,212 shares — an estimated $509K sold.
Royal Bank of Canada first reported a position in CNCE in Q1 2014 and held it in 32 quarters. The position peaked at $509K in Q4 2022. 0 funds tracked by Wall St. Rank hold CNCE as of Q1 2023.
- Royal Bank of Canada reported no remaining Concert Pharmaceuticals, Inc. position as of Q1 2023 after selling out during the quarter.
- Royal Bank of Canada sold 87,212 Concert Pharmaceuticals, Inc. shares in Q1 2023, an estimated $509K.
- Royal Bank of Canada first reported a position in Concert Pharmaceuticals, Inc. in Q1 2014 and held it in 32 quarters.
- Royal Bank of Canada's Concert Pharmaceuticals, Inc. position peaked at $509K in Q4 2022.
- 0 funds tracked by Wall St. Rank held Concert Pharmaceuticals, Inc. as of Q1 2023.
Based on Royal Bank of Canada's 13F filing for Q1 2023, filed 15 May 2023.